Iron increases the susceptibility of multiple myeloma cells to bortezomib

Haematologica

Volumn 98, Issue 6, 2013, Pages 971-979

  Campanella, Alessandro ^a   Santambrogio, Paolo ^a   Fontana, Francesca ^a   Frenquelli, Michela ^a   Cenci, Simone ^a   Marcatti, Magda ^a   Sitia, Roberto ^a,b   Tonon, Giovanni ^a   Camaschella, Clara ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BORTEZOMIB; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; FERRITIN; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; SYNDECAN 1;

APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; CANCER SUSCEPTIBILITY; CELL VIABILITY; DENSITOMETRY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IRON OVERLOAD; LIMIT OF QUANTITATION; MULTIPLE MYELOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; TREATMENT OUTCOME; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FERRITINS; HUMANS; INHIBITORY CONCENTRATION 50; IRON; MULTIPLE MYELOMA; PLASMA CELLS; PYRAZINES;

EID: 84878442520     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.074872     Document Type: Article

References (30)

1. Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, et al. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010;116(18):3635-44.
2. Katodritou E, Ganz T, Terpos E, Verrou E, Olbina G, Gastari V, et al. Sequential evaluation of serum hepcidin in anemic myeloma patients: study of correlations with myeloma treatment, disease variables, and anemia response. Am J Hematol. 2009; 84(8):524-6.
3. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell. 2010;142(1):24-38.
4. Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem J. 2011;434 (3):365-81.
5. Garrick MD. Human iron transporters. Genes and nutrition. 2011;6(1):45-54.
6. Arosio P, Levi S. Cytosolic and mitochondrial ferritins in the regulation of cellular iron homeostasis and oxidative damage. Biochim Biophys Acta. 2010;1800(8):783-92.
7. Recalcati S, Minotti G, Cairo G. Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid Redox Sign. 2010;13(10):1593-616.
8. Chauhan D, Hideshima T, Anderson KC. Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol. 2005;45:465-76.
9. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl J Med. 2003;348(26):2609-17.
10. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006;57:33-47.
11. Rouault TA. The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol. 2006;2(8):406-14.
12. Wang J, Fillebeen C, Chen G, Biederbick A, Lill R, Pantopoulos K. Iron-dependent degradation of apo-IRP1 by the ubiquitinproteasome pathway. Mol Cell Biol. 2007; 27(7):2423-30.
13. Matsunaga T, Kotamraju S, Kalivendi SV, Dhanasekaran A, Joseph J, Kalyanaraman B. Ceramide-induced intracellular oxidant formation, iron signaling, and apoptosis in endothelial cells: protective role of endogenous nitric oxide. J Biol Chem. 2004;279 (27):28614-24.
14. Kotamraju S, Kalivendi S, Shang T, Kalyanaraman B. Nitric oxide, proteasomal function, and iron homeostasis--implications in aging and neurodegenerative diseases. Methods Enzymol. 2005;396:526-34.
15. Zhang Y, Mikhael M, Xu D, Li Y, Soe-Lin S, Ning B, et al. Lysosomal proteolysis is the primary degradation pathway for cytosolic ferritin and cytosolic ferritin degradation is necessary for iron exit. Antioxid Redox Sign. 2010;13(7):999-1009.
16. De Domenico I, Vaughn MB, Li L, Bagley D, Musci G, Ward DM, et al. Ferroportinmediated mobilization of ferritin iron precedes ferritin degradation by the proteasome. Embo J. 2006;25(22):5396-404.
17. De Domenico I, Ward DM, Kaplan J. Specific iron chelators determine the route of ferritin degradation. Blood. 2009;114 (20):4546-51.
18. Cozzi A, Rovelli E, Frizzale G, Campanella A, Amendola M, Arosio P, et al. Oxidative stress and cell death in cells expressing Lferritin variants causing neuroferritinopathy. Neurobiol Dis. 2010;37(1):77-85.
19. Cozzi A, Corsi B, Levi S, Santambrogio P, Albertini A, Arosio P. Overexpression of wild type and mutated human ferritin Hchain in HeLa cells: in vivo role of ferritin ferroxidase activity. J Biol Chem. 2000;275 (33):25122-9.
20. Yu Y, Richardson DR. Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem. 2011;286(17):15413-27.
21. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, et al. Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med. 2010;2(43):43ra56.
22. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113(13):3040-9.
23. Nerini-Molteni S, Ferrarini M, Cozza S, Caligaris-Cappio F, Sitia R. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib. Br J Haematol. 2008;141(4):494-503.
24. Tsuji Y, Ayaki H, Whitman SP, Morrow CS, Torti SV, Torti FM. Coordinate transcriptional and translational regulation of ferritin in response to oxidative stress. Mol Cell Biol. 2000;20(16):5818-27.
25. Kotamraju S, Tampo Y, Keszler A, Chitambar CR, Joseph J, Haas AL, et al. Nitric oxide inhibits H2O2-induced transferrin receptor-dependent apoptosis in endothelial cells: Role of ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 2003;100(19):10653-8.
26. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood. 2006;107(12):4907-16.
27. van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO, et al. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feedback loop. J Clin Invest. 1996;98(6):1441-8.
28. Theurl I, Theurl M, Seifert M, Mair S, Nairz M, Rumpold H, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008;111(4): 2392-9.
29. Weiss G, Goodnough LT. Anemia of chronic disease. New Engl J Med. 2005;352(10): 1011-23.
30. Cullis JO. Diagnosis and management of anaemia of chronic disease: current status. Br J Haematol. 2011;154(3):289-300.